RemeGen (HKG:9995) said it was lifting the price cap on the repurchase of its shares from the open market, according to a Hong Kong bourse filing Thursday.
Shares of the biopharmaceutical research company gained nearly 3% in morning trade Friday.
The firm will now pay up to 116 yuan per share as opposed to the previous cap of 95 million yuan apiece previously.
The company's board approved a share repurchase program in December to buy back between 20 million yuan and 40 million yuan worth of stocks.